Durvalumab / Imfinzi Defies Expectations in MIBC, Offering Survival Gains Beyond Complete Response in NIAGARA Trial – ASCO GU 2025 ASCO GU 3 Mins Read Transforming MIBC Treatment: Insights from the NIAGARA Trial Posted on February 16, 2025 The landscape of treating muscle-invasive bladder cancer…
FDA Approves Durvalumab / IMFINZI® for Resectable NSCLC Non-Small Cell Lung Cancer Lung Cancer Treatment 3 Mins Read On August 15, 2024, the U.S. Food and Drug Administration (FDA) approved durvalumab (IMFINZI®, AstraZeneca) in combination with platinum-containing chemotherapy…
